A Phase 1 interventional study of empagliflozin medium dose and empagliflozin high dose in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 11 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-19.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 92nd largest by enrollment of the 96 interventional ones that give a count, is one of 7 that started in 2014, is one of 19 in phase 1, and was the 80th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 302 across the 96 interventional studies, 10,286 across the 34 observational. Of the 125 that completed or were terminated, 109 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient to receive a high dose of empagliflozin
Drug: empagliflozin high dose
Patient to receive a medium dose of empagliflozin
Drug: empagliflozin medium dose
Patient to receive a low dose of empagliflozin
Drug: empagliflozin low dose
AUC0-inf
Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).
Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).
Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Cmax
Maximum measured concentration in plasma (Cmax).
Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Tmax
Maximum measured concentration in plasma (tmax).
Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
t1/2
Terminal half-life in plasma (t1/2).
Time frame: Before drug administration (-0:30 hours (h)) and 0:30h, 1:00h, 1:30h, 2:00h, 4:00h, 8:00h, 12:00 (Day 1), 24:00 (Day 2), 34:00 (Day 2), 48:00 (Day 3) after drug administration.
Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake
Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake. For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'UGE at baseline' and 'FPG at baseline' as continuous covariates. Means presented are the adjusted means.
Time frame: baseline and 24 hours
Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake
Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake. For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'FPG at baseline' as continuous covariate. Means presented are the adjusted means.
Time frame: baseline and 24 hours
Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake
Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1). For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as fixed effect and 'MDG at baseline' as continuous covariate. Means presented are the adjusted means.
Time frame: baseline and 24 hours
| Milestone | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| Started | 9 | 8 | 10 |
| Completed | 9 | 8 | 10 |
| Not completed | 0 | 0 | 0 |
Area under the concentration-time curve of analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).
| nmol*h/L | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| AUC0-inf | 1150 ± 47.6 | 1430 ± 17.2 | 5060 ± 29.5 |
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable concentration (AUC0-tz).
| nmol*h/L | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| AUC0-tz | 1110 ± 49.9 | 1400 ± 17.1 | 4980 ± 29.1 |
Maximum measured concentration in plasma (Cmax).
| nmol/L | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| Cmax | 159 ± 44.5 | 188 ± 50.2 | 602 ± 61.1 |
Maximum measured concentration in plasma (tmax).
| hours | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| Tmax | 1.50 (0.95 to 7.92) | 1.25 (0.97 to 4.17) | 1.78 (0.50 to 4.00) |
Terminal half-life in plasma (t1/2).
| hours | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| t1/2 | 6.92 ± 19.4 | 7.35 ± 29.3 | 7.80 ± 29.6 |
Change from baseline in Urinary Glucose Excretion (UGE) over 24 h after study drug intake. For the changes from baseline in UGE on Day 1 (0 to 24 h postdose) , adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'UGE at baseline' and 'FPG at baseline' as continuous covariates. Means presented are the adjusted means.
| g/24h | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| Change From Baseline in Urinary Glucose Excretion (UGE) Over 24 h After Study Drug Intake | 53.1 ± 10.24 | 73.0 ± 10.14 | 87.4 ± 9.39 |
Change from baseline in Fasting Plasma Glucose (FPG) at 24h after study drug intake. For the change from baseline in FPG at 24 h postdose (in the morning of Day 2), adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as a fixed effect and 'FPG at baseline' as continuous covariate. Means presented are the adjusted means.
| mg/dL | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) at 24 h After Study Drug Intake | -15.5 ± 6.53 | -16.6 ± 6.29 | -20.4 ± 5.68 |
Change from baseline in 8-point plasma glucose profile over 24h after study drug intake (as defined by change from baseline in Mean Daily Glucose (MDG) calculated at Day 1). For the changes from baseline in MDG on Day 1, adjusted means per treatment group were to be calculated based on an ANCOVA including 'treatment' as fixed effect and 'MDG at baseline' as continuous covariate. Means presented are the adjusted means.
| mg/dL | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| Change From Baseline in 8-point Plasma Glucose Profile Over 24 h After Study Drug Intake | -12.9 ± 7.95 | -6.5 ± 9.21 | -13.2 ± 7.00 |
Collected over All adverse events reported within 7 days following trial drug administration were considered on treatment, up to 8 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Empagliflozin 5mg | — | 0/9 (0%) | 4/9 (44.4%) |
| Empagliflozin 10mg | — | 0/8 (0%) | 1/8 (12.5%) |
| Empagliflozin 25mg | — | 0/10 (0%) | 2/10 (20%) |
| Event | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg |
|---|---|---|---|
| DehydrationMetabolism and nutrition disorders | 0/9 | 1/8 | 0/10 |
| Anal pruritusGastrointestinal disorders | 1/9 | 0/8 | 0/10 |
| VomitingGastrointestinal disorders | 1/9 | 0/8 | 0/10 |
| NasopharyngitisInfections and infestations | 1/9 | 0/8 | 0/10 |
| HeadacheNervous system disorders | 1/9 | 0/8 | 1/10 |
| Abdominal painGastrointestinal disorders | 0/9 | 0/8 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 0/8 | 1/10 |
| Ligament sprainInjury, poisoning and procedural complications | 0/9 | 0/8 | 1/10 |
Treated Set (TS): The TS included all patients who were allocated trial medication and had received trial medication (empagliflozin).
| Age, Continuous(Years) | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg | Total |
|---|---|---|---|---|
| Mean | 13.7 ± 2.0 | 14.5 ± 1.9 | 14.2 ± 2.1 | 14.1 ± 2.0 |
| Sex: Female, Male(Participants) | Empagliflozin 5mg | Empagliflozin 10mg | Empagliflozin 25mg | Total |
|---|---|---|---|---|
| Female | 6 | 5 | 7 | 18 |
| Male | 3 | 3 | 3 | 9 |
The record gives a start of Jun 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.